STAT

DECEMBER 1, 2023

between 2004 and 2020 found that those who had cranial surgery, which involves removing or disconnecting the brain portion where seizures occur, were 83% more likely to be alive after 10 years. The study of 18,000 children who were treated at 49 pediatric hospitals in the U.S.

Insurance 130

Insurance Hospitals 130

STAT

NOVEMBER 15, 2023

Between 2004 and 2021, a U.S. Food and Drug Administration were more frequently invalidated due to information misrepresented or withheld from patent examiners than any other industry sector, according to a new analysis.

FDA 120

FDA 120

STAT

DECEMBER 2, 2022

In 2004, Mike Rossner and Kenneth Yamada, two top editors at the Journal of Cell Biology, wrote an editorial alerting readers to what they saw as an emerging problem in science: Thanks to Photoshop, researchers could prettify the images in their manuscripts in ways that might cross the line into deception in an effort to clear the bar of peer review. (..)

108

108

Pharmacy Times

FEBRUARY 14, 2024

Iloprost had also received Priority Review and Orphan Drug Designations for this indication, and FDA approval in 2004 for the treatment of pulmonary arterial hypertension.

FDA 81

FDA 81

STAT

FEBRUARY 21, 2023

billion worth of Humira in the Netherlands between 2004 and 2018, when its patents provided a monopoly. In making its case, the Pharmaceutical Accountability Foundation argued AbbVie allegedly overcharged the Dutch health care system by up to $1.2 billion by “abusing” its position in the marketplace and keeping prices high.

98

98

STAT

DECEMBER 7, 2023

Celgene later submitted study data to the Food and Drug Administration in its application for regulatory approval, but did not simultaneously seek additional patents on these other forms for another five years — in 2004.

FDA 120

FDA Compounding Pharmaceutical Companies Pharmaceutical Companies 120

STAT

JULY 10, 2023

A district manager for a convenience store chain, he first noticed symptoms in 2004 when his voice would suddenly falter while speaking to large groups of employees. It took Richard Huckabee nine years to get a Parkinson’s diagnosis. “It’s probably just stress,” Huckabee remembered his doctor saying.

98

98

STAT

SEPTEMBER 3, 2024

Between 1998 and 2004, the five-year survival rate for the disease has increased from 33% to 61%, according to the MMRF. The group has raised more than $600 million for research, launched nearly 100 clinical trials, and helped bring more than 15 new drugs to market.

Insurance 144

Insurance 144

STAT

MARCH 30, 2023

Since 2004, Barnes has been running the Minority Aging Research Study, one of the nation’s largest studies of Alzheimer’s focused exclusively on Black people and has created a brain bank used by other researchers to understand the illness in this population.

98

98

IDStewardship

JUNE 18, 2023

Adopting the name, “ IDPodcasts ,” the project (the term “podcast” was coined by a BBC journalist in 2004) sought to adapt infectious diseases presentations to a format recently popularized by the popular iPod music player of the 2000’s. ID Podcasts’ first podcast, “A Tour of the London Museum of Science,” was posted in June 2007.

Hospitals 217

Hospitals 217

Oswald's

MARCH 6, 2025

A significant milestone was the relocation to Naperville Plaza in 2004, positioning the pharmacy to better serve a growing customer base. My dad, Bill Anderson, and his siblings took over the business in 1991. Under their guidance, Oswald’s adapted to market shifts by expanding our gift and toy selections.

Customer Service 52

Customer Service 52

pharmaphorum

MARCH 5, 2021

After studying engineering at Cambridge University, Boyle founded Owlstone Inc in 2004 with a focus on sensor technology for military and industrial applications. It could help diagnose a huge range of diseases, including lung, bladder and breast cancer.

Compounding 98

Compounding 98

Pharmaceutical Technology

SEPTEMBER 10, 2024

The new biotech has inherited two T cell engager antibodies as part of a three-way merger with Vignette and TRC 2004.

52

52

The FDA Law Blog

JUNE 13, 2024

Citing to a 2004 Supreme Court case, Verizon Commc’ns., 398 (2004), Teva argued that Amneal has no cause of action under antitrust law because the Hatch-Waxman Amendments impose a new statutory duty on a company to cooperate with competitors and established a remedy for breach of that obligation. of Trinko, LLP , 540 U.S.

Dosage 116

Dosage FDA 116

STAT

MAY 3, 2024

Back in 2004, Gilead explained its decision by maintaining the medicines were not sufficiently different, but internal documents produced in court suggested the company made this move in order to maximize profits.

Documentation 104

Documentation 104

European Pharmaceutical Review

APRIL 14, 2023

stated that between 2004 and 2021, 23 NA therapeutics were approved. Gene therapy has offered exciting treatment opportunities for numerous severe and rare diseases that currently have no cure, the researchers noted. The current NA dosage forms and novel DDSs have enabled the successful launch of NA therapeutics globally. Ingle et al.

Dosage 105

Dosage Vaccines 105

Blog: Ask a Student Pharmacist

OCTOBER 4, 2023

Minneceutics Newsletter eomizowh Wed, 10/04/2023 - 12:47 Current Newsletter Expand all + Archive 1993 1994 1995 1999 2000 2001 2002 2003 2004 2006 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

52

52

STAT

FEBRUARY 15, 2024

An older version was approved in 2004 to treat pulmonary arterial hypertension, from a company now owned by Johnson & Johnson. The agency approved an Eicos Sciences intravenous drug, which works by opening up blood vessels, for reducing the risk of amputation for frostbitten fingers and toes.

Nursing Homes 97

Nursing Homes Hospitals 97

ISPE

FEBRUARY 13, 2023

Bob came to ISPE in 2004, furthering an already distinguished career in the pharmaceutical industry and as a regulator. After having worked in industry as a senior Quality Assurance position he joined the Therapeutic Goods Administration (TGA), Australia in 1971 as a GMP inspector.

Documentation 98

Documentation FDA 98

European Pharmaceutical Review

JUNE 24, 2022

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance).

Compounding 105

Compounding Packaging Dosage Communication 105

Pharmafile

MARCH 13, 2023

Gilead set up the Advancing Access medication assistance programme (MAP) in 2004 which aimed to provide eligible, uninsured people with free medication to protect them from contracting HIV. read more

52

52

European Pharmaceutical Review

JULY 10, 2023

The assessment report of the Committee for Medicinal Products for Human Use (CHMP)’s Article 5(3) of Regulation (EC) No 726/2004 opinion on nitrosamine impurities in human medicinal products offers guidance and recommendations on mitigation and prevention of nitrosamine-contaminated human medicinal products.

Documentation 98

Documentation FDA 98

pharmaphorum

DECEMBER 14, 2021

It has made cumulative loses of almost $650 million since being founded in 2004. .” Mesoblast said it was sitting on cash reserves of $116 million at the end of September, having spent just under $23 million in the prior three-month period. The post Mesoblast pummelled as Novartis exits COVID deal appeared first on.

Immunization 101

Immunization Vaccines FDA 101

pharmaphorum

NOVEMBER 16, 2022

Cases of drug-resistant TB (DR-TB) rose 3% in 2021 over the previous year, the first increase since record-keeping started in 2004, according to the WHO report, which called for countries to move quickly to restore access to essential services to treat the disease, as well as greater investment in new vaccines and therapeutics.

Compounding 98

Compounding Vaccines 98

European Pharmaceutical Review

JULY 7, 2022

At the beginning of his career in 2004, Dr Hughes was responsible for early clinical research at Bristol Myers-Squibb Company and then at Schering-Plough Research Institute. .” Since September 2021, Dr Hughes has been Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals, based in Boston.

Research Laboratories 98

Research Laboratories Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

European Pharmaceutical Review

FEBRUARY 10, 2023

Since joining Astellas Group (former Yamanouchi Group) in 2004, he has held various positions including Regional Senior Vice President, North Europe, Astellas Pharma Europe Ltd. He has experience in the commercial area at Schering and Bayer. Adam Pearson will be appointed as Chief Strategy Officer (CStO).

105

105

European Pharmaceutical Review

JULY 25, 2022

The new Regulation will replace the rules for safety and quality set out in Directives 2002/98/EC for blood and blood components and 2004/23/EC for tissues and cells, in addition to their implementing acts. .

116

116

Hospital Pharmacy Europe

AUGUST 14, 2023

The use of a six-month regimen of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) became the standard adjuvant therapy in stage 3 disease from 2004 when trials convincingly showed that the addition of oxaliplatin improved overall survival.

Chemotherapy 97

Chemotherapy Mayo Clinic Hospitals 97

Hospital Pharmacy Europe

JANUARY 26, 2023

In the present study, researchers undertook a cohort study, including patients aged 18 years and older who were prescribed hydroxychloroquine between 2004 and 2020 and who participated in retinal screening. female) were included and who had used the drug between 2004 and 2014 and then continued for a further 5 years. Overall, 65.4%

Hospitals 52

Hospitals 52

The Checkup by Singlecare

NOVEMBER 30, 2023

Sources Acetaminophen hepatotoxicity and nonsteroidal anti-inflammatory drug-related gastrointestinal and renal toxicity , Center for Drug Evaluation and Research (2004). Paracetamol (acetaminophen) interaction NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle , Thrombosis, and hemostasis (2004).

Immunization 98

Immunization Vaccines FDA Labelling 98

pharmaphorum

AUGUST 27, 2020

Founded in 2004, Baltimore-headquartered Discern Health provides strategic direction and policy solutions to life sciences companies, government and non-profit agencies, and health insurers. We will truly be #BetterTogether.”.

Communication 59

Communication Insurance 59

Hospital Pharmacy Europe

FEBRUARY 19, 2023

In addition to hospital admissions data, the team also collected information on COPD and asthma-related medicines prescribed between 2004 and 2020. increase the absolute number of COPD and asthma-related dispensed medicines between 2004 and 2020, which represented a 27.2% between 1999 and 2020 which represented a 59.1%

Hospitals 52

Hospitals 52

pharmaphorum

JUNE 22, 2021

There are two European-wide legal frameworks for patients to access planned treatment abroad: Social Security Regulations (EC) 883/2004 and 987/2009, and the Directive 2011/24/EU on patients’ rights in cross-border healthcare. The biggest distinction between these frameworks concerns payment.

Insurance 72

Insurance 72

The Checkup by Singlecare

SEPTEMBER 13, 2023

A 2004 study found that administering 25 mg/kg of metronidazole twice a day for seven days was effective and safe for stopping the shedding of giardia cysts in cats. The antibiotic also treats giardia infections.

Dosage 109

Dosage Adverse Reactions Hospitals Compounding 109

pharmaphorum

APRIL 20, 2022

The suit focuses on alleged abuse of Gilead’s Advancing Access programme, a scheme set up in 2004 to provide HIV therapies at no charge to people who lack heath insurance and would be unable to get access to the drugs.

Insurance 69

Insurance 69

European Pharmaceutical Review

JULY 26, 2022

The review was carried out under Article 20 of Regulation (EC) No 726/2004, which is triggered for centrally authorised medicines in case of quality, safety and efficacy issues.

Vaccines 105

Vaccines Chemotherapy 105

pharmaphorum

DECEMBER 28, 2022

In addition, she worked as head of inspectorate and licensing for the MHRA from 2004-2006. She joined NSF in 2017. The post How to get acquisition ready – a seller’s guide to merger and acquisition in pharma appeared first on.

Documentation 119

Documentation Pharmaceutical Companies Pharmaceutical Companies FDA 119